Shanghai scientists lead the development of new anti-Aids drugs approved for clinical

Chinese may soon have proprietary intellectual property rights for AIDS treatment drugsYesterday, two Shanghai scientists told reporters: anti-AIDS candidate new drug "Nifivero" has been approved by the State FoodDrugAdministration into clinical trialsI research institutions yesterday signed an contract with Australian enterprises to make the drug follow-up research and development into the fast track of international production and researchPreclinical trials have shown that "nifiviro" can effectively inhibit HIV intrusion into cells, in vitro anti-infection effect is comparable to similar international candidate drugs, and more development cost advantage" Since the first case of AIDS was detected in 1981, 65 million people have been infected and 25 million have died, affecting nearly 200 countries and regionsThe main link of HIV-infected cells is "intrusive cells - self-replication - release diffusion", because of the ability to specifically infect immune cells this "guard", the patient's body has become "an unguarded city." At present, the clinically widely used anti-AIDS drugs only act on the process of virus infection into cells, which can reduce the late stage of the disease, including death, including complications, prolong the survival of patientsBut it is extremely costly and prone to drug resistanceHow do I "block" a virus as it enters a cell? Since 2000, the Chinese Academy of Sciences Shanghai Institute of Life Sciences Biochemical Cell Institute of Yan Gang and the Chinese Academy of Sciences Shanghai Institute of Organic Chemistry Ma Dawei researcher began to cooperate, for HIV intrusion into the cell this starting link, in the new direction of anti-AIDS drugs research and development, to join the fierce international competitionOver the course of 3 years, they finally discovered several promising drug candidate molecules and applied for international patents" China's Western medicine "activity is no less than foreign drugworldwide, with "nifiviro" the same type of candidate drugs are not many, is in different stages of research and development, the fastest completed phase III clinical trials, is pressing ahead to apply for listingIn order to accelerate research and development, "Nifivero" has completed the first domestic industrial and research cooperationTwo research institutes with knowledge capital into the stock, and Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltdco-sponsored the formation of Shanghai Target Pharmaceutical Co., Ltd The young team of "Target" targeted these newly discovered drug molecules and successfully completed the preclinical research of the "Nifivero" major project of the Municipal Science and Technology Commission in less than 3 years The results showed that the drug can show strong antiviral activity on multi-drug-resistant HIV strains, and can be absorbed orally, with small side effects and high safety Compared with existing inhibitors that act in the late stages of viral infection, the "blocking source" mechanism is unlikely to develop resistance and is expected to become a drug to prevent the sexual transmission of AIDS Reducing the cost of research and development is to reduce drug prices before entering clinical trials, "Nifivero" and achieve the second international industrial production and research cooperation, the signing of the two sides are already AIDS candidate drug industrialization experience of the Australian Evik company, as well as Shanghai Target Company According to the agreement, The Chinese side is mainly responsible for research and development in drug chemistry and drug screening, retaining the market share of "Nifivero" in China (including Hong Kong, Macao and Taiwan) and sharing the intellectual property rights produced in subsequent research and development; It is understood that this agreement in accordance with the new drug creation of the international rules signed, will make the new drug market greatly accelerated Given the low cost of pre-research and development of the drug and the holding of independent intellectual property rights, it is expected that the price advantage is more than the imported drug, domestic patients will be the biggest beneficiaries (rereproduced from Liberation Daily)